Last reviewed · How we verify

ArtemiC — Competitive Intelligence Brief

ArtemiC (ArtemiC) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Cannabis-derived pharmaceutical.

marketed Cannabis-derived pharmaceutical Small molecule Live · refreshed every 30 min

Target snapshot

ArtemiC (ArtemiC) — MGC Pharmaceuticals d.o.o. ArtemiC is a cannabis-based pharmaceutical product that delivers cannabinoids for therapeutic effect.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ArtemiC TARGET ArtemiC MGC Pharmaceuticals d.o.o marketed Cannabis-derived pharmaceutical

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Cannabis-derived pharmaceutical class)

  1. MGC Pharmaceuticals d.o.o · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ArtemiC — Competitive Intelligence Brief. https://druglandscape.com/ci/artemic. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: